182 related articles for article (PubMed ID: 23166089)
1. Drugs by numbers: reaction-driven de novo design of potent and selective anticancer leads.
Spänkuch B; Keppner S; Lange L; Rodrigues T; Zettl H; Koch CP; Reutlinger M; Hartenfeller M; Schneider P; Schneider G
Angew Chem Int Ed Engl; 2013 Apr; 52(17):4676-81. PubMed ID: 23166089
[TBL] [Abstract][Full Text] [Related]
2. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
[TBL] [Abstract][Full Text] [Related]
3. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
[TBL] [Abstract][Full Text] [Related]
5. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
6. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
Rheault TR; Donaldson KH; Badiang-Alberti JG; Davis-Ward RG; Andrews CW; Bambal R; Jackson JR; Cheung M
Bioorg Med Chem Lett; 2010 Aug; 20(15):4587-92. PubMed ID: 20594842
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.
Keppner S; Proschak E; Schneider G; Spänkuch B
ChemMedChem; 2009 Nov; 4(11):1806-9. PubMed ID: 19746360
[No Abstract] [Full Text] [Related]
9. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
Chen DX; Huang J; Liu M; Xu YG; Jiang C
Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
[TBL] [Abstract][Full Text] [Related]
10. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
[TBL] [Abstract][Full Text] [Related]
11. Vanillin-derived antiproliferative compounds influence Plk1 activity.
Carrasco-Gomez R; Keppner-Witter S; Hieke M; Lange L; Schneider G; Schubert-Zsilavecz M; Proschak E; Spänkuch B
Bioorg Med Chem Lett; 2014 Nov; 24(21):5063-9. PubMed ID: 25304894
[TBL] [Abstract][Full Text] [Related]
12. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
13. Developing polo-like kinase 1 inhibitors.
Huang X; Xie Z; Liao C
Future Med Chem; 2020 May; 12(10):869-871. PubMed ID: 32233804
[No Abstract] [Full Text] [Related]
14. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
Sun J; Lv PC; Guo FJ; Wang XY; Xiao-Han ; Zhang Y; Sheng GH; Qian SS; Zhu HL
Eur J Med Chem; 2014 Jun; 81():420-6. PubMed ID: 24859762
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
[TBL] [Abstract][Full Text] [Related]
16. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
[TBL] [Abstract][Full Text] [Related]
17. Pinning down the polo-box domain.
Lee KS; Idle JR
Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691
[TBL] [Abstract][Full Text] [Related]
18. Targeting polo-like kinase: learning too little too late?
Olmos D; Swanton C; de Bono J
J Clin Oncol; 2008 Dec; 26(34):5497-9. PubMed ID: 18955441
[No Abstract] [Full Text] [Related]
19. 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.
Beria I; Valsasina B; Brasca MG; Ceccarelli W; Colombo M; Cribioli S; Fachin G; Ferguson RD; Fiorentini F; Gianellini LM; Giorgini ML; Moll JK; Posteri H; Pezzetta D; Roletto F; Sola F; Tesei D; Caruso M
Bioorg Med Chem Lett; 2010 Nov; 20(22):6489-94. PubMed ID: 20932759
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]